Prognostic role of nuclear factor/IB and bone remodeling proteins in metastatic giant cell tumor of bone: A retrospective study
Open Access
- 12 March 2015
- journal article
- research article
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 33 (8) , 1205-1211
Abstract
Giant cell tumor of bone (GCTb) represents 5% of bone tumors, and although considered benign, 5% metastasize to the lung. The expression of proteins directly or indirectly associated with osteolysis and tumor growth was studied on 163 samples of GCTb. Of these, 33 patients developed lung metastasis during follow‐up. The impact of tumor–host interaction on clinical aspects was evaluated with the aim of finding specific markers for new biological therapies, thus improving clinical management of GCTb. Protein expression was evaluated by immunohistochemical analysis on Tissue Microarray. The majority of GCTb samples from patients with metastatic disease were strongly positive to RANKL and its receptor RANK as well as to CAII and MMP‐2 and to pro‐survival proteins NFIB and c‐Fos. Kaplan–Meier analysis indicated a significant difference in metastasis free survival curves based on protein staining. Interestingly, the statistical correlation established a strong association between all variables studied with a higher τ coefficient for RANK/RANKL, RANK/NFIB, and RANKL/NFIB pairs. At multivariate analysis co‐overexpression of NFIB, RANK and RANKL significantly increased the risk of metastasis with an odds ratio of 13.59 (95%CI 4.12–44.82; p < 0.0005). In conclusion, the interconnection between matrix remodeling and tumor cell activity may identify tumor–host endpoints for new biological treatments. © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 33:1205–1211, 2015.Keywords
Funding Information
- EU FP7 Eurosarc, BioBanca Oncologia Emilia Romagna
- Fondazione Italiana per la Ricerca sul Cancro (FIRC) (13748)
This publication has 19 references indexed in Scilit:
- Giant cell tumor of bone: A basic science perspectiveBone, 2013
- Soluble Rank Ligand Produced by Myeloma Cells Causes Generalised Bone Loss in Multiple MyelomaPLOS ONE, 2012
- An Osteoblast-Derived Proteinase Controls Tumor Cell Survival via TGF-beta Activation in the Bone MicroenvironmentPLOS ONE, 2012
- Modern Interpretation of Giant Cell Tumor of Bone: Predominantly Osteoclastogenic Stromal TumorClinics in Orthopedic Surgery, 2012
- NFIB is a potential target for estrogen receptor‐negative breast cancersMolecular Oncology, 2011
- Nuclear factor I/B is an oncogene in small cell lung cancerGenes & Development, 2011
- Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma modelsJournal of Bone and Mineral Research, 2011
- Identification of Potential Biomarkers for Giant Cell Tumor of Bone Using Comparative Proteomics AnalysisThe American Journal of Pathology, 2011
- RANKL expression is related to treatment outcome of patients with localized, high‐grade osteosarcomaPediatric Blood & Cancer, 2010
- Metastatic Giant Cell Tumor of Bone: Are There Associated Factors and Best Treatment Modalities?Clinical Orthopaedics and Related Research, 2010